Honeywell has partnered with the Peter MacCallum Cancer Centre in Melbourne to provide advanced building technologies for the Centre’s new A$105 million biomedical manufacturing facility.
This facility, designed to produce innovative cell-based cancer therapies, is a significant step forward in commercial-scale manufacturing of treatments such as CAR T-cell therapy.
Opened in 2023, the facility houses critical environments for cancer treatment production, and Honeywell’s advanced answers ensure stringent control over air quality, energy usage, security, and other building systems. These technologies are crucial for maintaining compliance with strict biomedical manufacturing standards and ensuring optimal conditions for research and production.
Professor Simon Harrison, Executive Director of Cancer Research at Peter MacCallum, expressed enthusiasm for the collaboration, stating that it enables the development and delivery of life-changing treatments.
“This partnership with Honeywell allows us to focus on what we do best – treating patients – while their technology ensures our facility operates at the highest possible standard,” Harrison said.
Laura Laltrello, Honeywell’s Vice President and General Manager of Building Technologies, said, “We’re proud to be part of such a pioneering project. Our technologies not only help to create a safe and efficient production environment but also contribute to the future of cancer treatment.”
This collaboration represents a milestone in combining healthcare innovation with smart building technologies, aiming to advance medical and operational excellence in Australia’s biomedical sector.